Daily Tournal DECEMBER 4, 2024

TOPANTITRUST LAMYERS 2024





JOSEPH R. SAVERI JOSEPH SAVERI LAW FIRM SAN FRANCISCO

ith 30 years of experience, Joseph Saveri is recognized as one of the country's top litigators in the plaintiffs-side bar. Throughout his career, he has investigated, prosecuted, and successfully resolved numerous antitrust class actions and other complex cases, achieving groundbreaking rulings.

His firm's attorneys have garnered numerous accolades, rivaling those of larger and more established firms and have generated over \$4.7 billion in settlements and successful resolutions for their clients.

A year ago, Saveri and his firm were preparing to go to trial in three major antitrust lawsuits they had filed. By spring, all three cases had settled.

In March, Saveri's team secured an \$82.5 million settlement for families of competitive cheerleaders from the dominant cheer organization they accused of price-fixing. *Jones v. Varsity Brands*, 2:20-cv-02892 (W.D. Tenn., filed Aug. 20, 2020). In June, the Court granted preliminary approval of the settlement.

In April, they achieved a \$10.8 million all-cash settlement from two major tax-preparation services that had agreed not to compete for each other's employees or potential hires. *Robinson v. Jackson Hewitt Inc.*, 2:19-cv-09066 (D. N.J., filed May 28, 2019). In November, the Court granted final settlement approval.

The most significant settlement achieved by the Saveri firm was \$375 million for approximately 2,000 professional mixed-martial arts fighters. These fighters contended that the Ultimate Fighting Championship company dominated their sport, suppressing their pay and keeping other potential employers out of the market. One estimate put the fighters' lost income at as much as \$1.6 billion. Le v. Zuffa LLC, 2:15-cv-01045 (D. Nev., filed Dec. 5, 2017). The Court has granted preliminary approval of the settlement.

Saveri said he takes pride in his firm's history of pushing antitrust law into new areas. He noted that his firm pioneered "no-poach" antitrust claims, like the Jackson Hewitt tax preparation case, as well as "reverse payment" drug cases against pharmaceutical companies that pay other drug makers not to bring out generics.

"We're willing to take on these challenges and really create a whole new area of the law," Saveri said.